Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 110

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 110
---
 to completion      
 of this offering. The information set forth in the footnotes is based upon our information                                                  
 and belief, the records of the Company and the selling stockholder’s filing with the SEC, if any.                                           |

| (2) | The selling                                                                                                                                     
 shareholder holds warrants issued by us in prior transactions which entitle the selling shareholder to purchase an aggregate of 417,940,000     
 Ordinary Shares (in the form of Depositary Shares), and (ii) Series J Warrants issued by us which entitle the selling shareholder to            
 purchase an aggregate of 212,760,000 Ordinary Shares (in the form of Depositary Shares) and Series K Warrants issued by us which entitle        
 the selling shareholder to purchase an aggregate of 212,760,000 Ordinary Shares (in the form of Depositary Shares) and which we are registering 
 hereby. The warrants are subject to a beneficial ownership limitation of 9.99%, which does not permit the selling shareholder to exercise       
 that portion of the warrants that would result in the selling shareholder and its affiliates owning, after exercise, a number of our            
 Ordinary Shares in excess of the beneficial ownership limitation. The amounts and percentages in the table do not give effect to the            
 9.99% beneficial ownership limitation, if applicable. The principal business address of Bigger Capital Fund, LP is 11700 West Charleston        
 Blvd, #170-659, Las Vegas, NV 89135.                                                                                                            |

| (3) | The selling shareholder holds (i)                                                                                                         
 warrants issued by us in prior transactions which entitle the selling shareholder to purchase an aggregate of 309,660,000 Ordinary Shares 
 (in the form of Depositary Shares), and (ii) Series J Warrants issued by us which entitle the selling                                     
 shareholder to purchase an aggregate of 425,530,000 Ordinary Shares (in the form of Depositary Shares) and Series K Warrants issued by    
 us which entitle the selling shareholder to purchase an aggregate of 425,530,000 Ordinary Shares (in the form of Depositary Shares) and   
 which we are registering hereby. The warrants are subject to a beneficial ownership limitation of 4.99%, which does not permit            
 the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder and its affiliates owning,  
 after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts and percentages in the      
 table do not give effect to the